Skip to main
CNTB
CNTB logo

CNTB Stock Forecast & Price Target

CNTB Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Connect Biopharma Holdings Ltd has demonstrated significant potential with its candidate rademikibart, which exhibited one of the largest reported improvements in FEV1 for any biologic during its Phase 2 asthma study, indicating its effectiveness in both acute and chronic treatment scenarios. The anticipated completion of IV dosing strategies and the expected clinical data by the end of 2025 suggest a promising commercial future, potentially increasing market uptake and revenue. Additionally, rademikibart's demonstrated rapid improvements in lung function, especially in eosinophilic subgroups, distinguishes it from existing chronic treatments, further reinforcing a positive outlook for the company's stock.

Bears say

Connect Biopharma Holdings Ltd faces significant challenges that contribute to a negative outlook for its stock. Increased competition within the biopharmaceutical market could restrict the company's market share and lead to sales outcomes below expectations. Additionally, potential patent disputes, difficulties in securing reimbursement, and the risk of unsuccessful clinical trial results may further undermine Connect's competitive position and revenue prospects.

CNTB has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Connect Biopharma Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Connect Biopharma Holdings (CNTB) Forecast

Analysts have given CNTB a Strong Buy based on their latest research and market trends.

According to 2 analysts, CNTB has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Connect Biopharma Holdings (CNTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.